AUTHORS
Joseph Van Galen, MD, MS, Xia Bi, MD2, Boula Gattas, MD3, Onder Alpdogan, MD4, William O'Hara5, Theresa Gorman6, Joanne Filicko-O'Hara, MD7, Usama Gergis, MD, MBA8
AFFILIATIONS
1 Thomas Jefferson University, Philadelphia, United States
2 Thomas Jefferson University, Philadelphia, United States
3 Thomas Jefferson University, Philadelphia, United States
4 Thomas Jefferson University, Philadelphia, United States
5 Thomas Jefferson University, Philadelphia, United States
6 Thomas Jefferson University, Philadelphia, United States
7 Thomas Jefferson University, Philadelphia, United States
8 Thomas Jefferson University, Philadelphia, United States
ABSTRACT
Background
Cytokine release syndrome (CRS), also referred to as haploimmunostorm, remains a clinically significant complication of HLA-mismatched and haploidentical allogeneic hematopoietic stem cell transplantation (HSCT) despite the widespread adoption of post-transplant cyclophosphamide (PTCy). CRS severity correlates with degree of HLA mismatch and has been associated with increased transplant-related mortality. Tocilizumab, an interleukin-6 receptor antagonist, is routinely used for treatment of CRS following adoptive cellular therapies and has been used to treat HSCT-associated CRS. Nevertheless, evidence supporting its safety and efficacy remains limited to small retrospective series.
Methods
We retrospectively analyzed results of consecutive adult-recipient peripheral blood stem cell allogeneic HSCT procedures performed using donors other than 8/8 HLA-matched donors in this IRB-approved study. HSCT was performed using either a standard PTCy-based graft-versus-host disease (GVHD) prophylaxis regimen or our institutional two-step transplantation platform. Patients included in this series were diagnosed with severe CRS, defined as either isolated temperature ≥40°C or fever ≥38°C accompanied by fluid-refractory hypotension and/or a new supplemental oxygen requirement, with grading adapted from the ASTCT CRS Consensus criteria. Advanced severe CRS was defined within the broader cohort by hypotension or hypoxia. All patients diagnosed with both advanced and non-advanced severe CRS received intravenous tocilizumab (8 mg/kg; maximum dose 800 mg) over one hour. Additional doses were permitted every 8 hours for persistent symptoms, up to four total doses (maximum three doses within 24 hours). Overall survival (OS), graft-versus-host disease-free/relapse-free survival (GRFS), and hematopoietic engraftment were evaluated and stratified by advanced versus non-advanced severe CRS diagnosis.
Results
Thirty-five consecutive patients received tocilizumab for severe HSCT-associated CRS between May 2023 and February 2026. Nineteen patients received grafts from donors matched at six to nine HLA loci, while sixteen underwent haploidentical transplantation. Median time to neutrophil engraftment was 19.5 days (IQR [18.0, 22.0]), median time to platelet engraftment was 28 days (IQR [22.0, 38.0]). One-year overall survival rate was 71.4% (median OS days not estimable, IQR [286, not reached]). One-year GRFS rate was 37.1% (median GRFS 134 days, IQR [96,179]). No difference in engraftment times or survival times were observed when comparing patients with non-advanced to advanced severe CRS. Acute (grade II-IV) and chronic GVHD were observed, respectively, in 31.6% and 5.3% of patients treated with donor grafts matched at between six and nine HLA loci, and in 25.0% and 18.8% of patients treated with haploidentical donor products.
Conclusions
CRS remains an important complication of mismatched donor HSCT and has previously been associated with inferior transplant outcomes. In this largest reported cohort of patients treated with tocilizumab for HSCT-associated CRS, favorable survival, GRFS, and hematopoietic recovery were maintained regardless of initial CRS severity, suggesting that IL-6 blockade may mitigate the adverse clinical impact of severe CRS without compromising engraftment or long-term transplant outcomes. These findings support prospective multicenter evaluation of tocilizumab as standard therapy for severe CRS following mismatched and haploidentical allogeneic HSCT.
DISCLOSURES
Joseph Van Galen, MD, MS: No relevant conflicts of interest to declare.